Yes, the recommended adjuvant treatment is immune therapy.
Adjuvant pembrolizumab, an immune checkpoint inhibitor targeting PD-1, is now the strongly recommended standard of care for patients with high-risk clear-cell renal cell carcinoma after nephrectomy, including those with pathologic stage T3/T4, N+, or grade 3-4 disease. 1
Evidence Supporting Immune Therapy
The 2025 European Association of Urology guidelines issued a strong recommendation for adjuvant pembrolizumab based on mature data from the KEYNOTE-564 trial, which demonstrated:
- Significant overall survival benefit (HR 0.62,95% CI 0.44-0.87; p = 0.005) 1
- Improved disease-free survival in patients with intermediate-high risk or high-risk clear-cell RCC 1
- No deterioration in quality of life according to evaluable evidence 1
This represents a fundamental shift from the previous weak recommendation, now upgraded due to mature survival data that directly impact mortality—the most critical outcome.
Specific Patient Eligibility
Your patient with pathologic stage T3/T4, N+, grade 3-4 clear-cell RCC fits precisely within the KEYNOTE-564 trial criteria, which included:
- High-risk disease: pT4 any grade N0 M0, OR any pT stage with N+ M0
- Intermediate-high risk: pT3 any grade N0 M0
- M1 NED: Completely resected metastatic disease within 1 year of nephrectomy 1
Treatment Regimen
Pembrolizumab is administered as:
- 17 cycles of 3-weekly therapy (approximately 1 year of treatment) 1
Critical Caveats and Toxicity Discussion
A significant proportion of patients experience life-changing or serious side effects, which must be thoroughly discussed before initiating therapy 1. This is not a trivial consideration—the guidelines explicitly emphasize this counseling requirement despite the strong recommendation.
The historical context matters: decades of failed adjuvant trials with cytokines, VEGF-targeted agents, and mTOR inhibitors showed no benefit and often significant toxicity 2, 3. Pembrolizumab is the first agent to demonstrate both disease-free and overall survival benefits in this setting.
What About Other Immune Therapies?
Other immune checkpoint inhibitor strategies have failed to meet primary endpoints 1. The benefit is not class-wide—it is specific to pembrolizumab monotherapy in this population 2. Alternative ICI combinations tested in contemporaneous trials did not show the same benefit, underscoring that patient selection and specific treatment choice matter critically.
Post-Adjuvant Recurrence Considerations
If recurrence occurs during or shortly after adjuvant pembrolizumab:
- ICI monotherapy or combination therapy is NOT recommended (weak recommendation) 1
- This is based on negative results from TiNivo and CONTACT-03 trials evaluating subsequent ICI therapy after progression on ICI in the metastatic setting 1
- Consider switching mechanisms to VEGF-targeted or HIF-2α-targeted therapy for early recurrence, which may suggest primary immune resistance 4